Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Jul 24, 2025-

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine...

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Breakthrough: First-Ever EU Treatment Approved for Advanced Neuroendocrine Cancer Patients

CABOMETYX secures landmark EU approval as first-in-class therapy for advanced neuroendocrine tumors. Spans 27 EU countries plus 3 more. See trial results.